{"title":"Treatment Strategies for Subclavian Artery Occlusion: A Comparative Analysis of Endovascular Repair, Subclavian-Carotid Bypass, and Transposition.","authors":"Ke Zhang, Yuanrui Gu, Haorui Zhang, Yanxia Tu, Cuntao Yu, Chenxi Ouyang","doi":"10.1177/15266028251353408","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We aimed to compare the technical success rates and long-term patency of endovascular repair, subclavian-carotid bypass (SCB), and subclavian-carotid transposition (SCT) for subclavian artery occlusion.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 181 patients at Fuwai Hospital (2015-2024). Primary endpoint was the primary patency rate. Secondary endpoints included technical success, secondary patency and freedom from target lesion revascularization (TLR) rates. Kaplan-Meier analyses were applied.</p><p><strong>Results: </strong>One hundred and eighty-one patients [median age: 60 years, interquartile range (IQR) 54.00-65.00; 76.2% male) underwent 192 procedures, with 111 endovascular repairs, 38 SCBs, and 43 SCTs. Indications included vertebrobasilar insufficiency (39.2%), arm ischemia (28.7%), both (29.3%), cardiac causes (2.2%), and combined arm and cardiac indications (0.6%). The endovascular group had a lower technical success rate than SCB and SCT (86.5% vs 97.4% vs 100.0%). SCT had the longest lesion-to-vertebral artery (VA) length among the 3 groups. Ostial occlusion was more frequent and lesion length was longer in failed cases compared to successful cases (33.3% vs 6.3%, 14.50 vs 22.00 mm). After a median follow-up of 44 months (IQR 22.00-70.00), SCT had the highest primary patency rate (100% at 1, 3, and 5 years) compared to endovascular repair (93.4%, 88.2%, 77.6%) and SCB (94.1%, 86.8%, 72.3%; p=0.12). Endovascular group had primary patency, secondary patency, and freedom from TLR rates comparable to open surgery (SCB and SCT). SCB had lower primary patency than SCT.</p><p><strong>Conclusions: </strong>Endovascular repair offers good long-term patency but requires careful patient selection due to higher technical failure rates. SCT is recommended for patients at high risk of endovascular failure, while SCB remains suitable for multi-segment, distal occlusions or lesions with a short lesion-to-VA length.Clinical ImpactTo our knowledge, this is the largest study comparing outcomes of endovascular repair, subclavian-carotid bypass (SCB), and transposition (SCT) for SA occlusion. We found that endovascular repair provides midterm patency comparable to open surgery and may serve as the preferred option in carefully selected patients-contrary to prior reports, possibly due to optimized antiplatelet therapy. Technical failure was more frequent in cases with ostial involvement or longer lesion length. Although SCB showed inferior patency to SCT, it remains preferable for complex, distal lesions, or those with short lesion-to-vertebral artery (VA) length. Our anatomical analysis may offer guidance for individualized treatment selection.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"15266028251353408"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endovascular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15266028251353408","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: We aimed to compare the technical success rates and long-term patency of endovascular repair, subclavian-carotid bypass (SCB), and subclavian-carotid transposition (SCT) for subclavian artery occlusion.
Methods: A retrospective analysis was conducted on 181 patients at Fuwai Hospital (2015-2024). Primary endpoint was the primary patency rate. Secondary endpoints included technical success, secondary patency and freedom from target lesion revascularization (TLR) rates. Kaplan-Meier analyses were applied.
Results: One hundred and eighty-one patients [median age: 60 years, interquartile range (IQR) 54.00-65.00; 76.2% male) underwent 192 procedures, with 111 endovascular repairs, 38 SCBs, and 43 SCTs. Indications included vertebrobasilar insufficiency (39.2%), arm ischemia (28.7%), both (29.3%), cardiac causes (2.2%), and combined arm and cardiac indications (0.6%). The endovascular group had a lower technical success rate than SCB and SCT (86.5% vs 97.4% vs 100.0%). SCT had the longest lesion-to-vertebral artery (VA) length among the 3 groups. Ostial occlusion was more frequent and lesion length was longer in failed cases compared to successful cases (33.3% vs 6.3%, 14.50 vs 22.00 mm). After a median follow-up of 44 months (IQR 22.00-70.00), SCT had the highest primary patency rate (100% at 1, 3, and 5 years) compared to endovascular repair (93.4%, 88.2%, 77.6%) and SCB (94.1%, 86.8%, 72.3%; p=0.12). Endovascular group had primary patency, secondary patency, and freedom from TLR rates comparable to open surgery (SCB and SCT). SCB had lower primary patency than SCT.
Conclusions: Endovascular repair offers good long-term patency but requires careful patient selection due to higher technical failure rates. SCT is recommended for patients at high risk of endovascular failure, while SCB remains suitable for multi-segment, distal occlusions or lesions with a short lesion-to-VA length.Clinical ImpactTo our knowledge, this is the largest study comparing outcomes of endovascular repair, subclavian-carotid bypass (SCB), and transposition (SCT) for SA occlusion. We found that endovascular repair provides midterm patency comparable to open surgery and may serve as the preferred option in carefully selected patients-contrary to prior reports, possibly due to optimized antiplatelet therapy. Technical failure was more frequent in cases with ostial involvement or longer lesion length. Although SCB showed inferior patency to SCT, it remains preferable for complex, distal lesions, or those with short lesion-to-vertebral artery (VA) length. Our anatomical analysis may offer guidance for individualized treatment selection.
背景:我们的目的是比较血管内修复、锁骨下颈动脉旁路(SCB)和锁骨下颈动脉转位(SCT)治疗锁骨下动脉闭塞的技术成功率和长期通畅度。方法:对阜外医院2015-2024年181例患者进行回顾性分析。主要终点为原发性通畅率。次要终点包括技术成功、二次通畅和无靶病变血运重建(TLR)率。应用Kaplan-Meier分析。结果:181例患者[中位年龄:60岁,四分位数间距(IQR) 54.00 ~ 65.00;76.2%的男性)接受了192次手术,111例血管内修复,38例scb和43例sct。适应症包括椎基底动脉功能不全(39.2%)、上肢缺血(28.7%)、两者均有(29.3%)、心脏原因(2.2%)和上肢和心脏联合适应症(0.6%)。血管内组的技术成功率低于SCB和SCT (86.5% vs 97.4% vs 100.0%)。SCT的病变到椎动脉(VA)长度在3组中最长。与成功病例相比,失败病例的口闭塞更频繁,病变长度更长(33.3% vs 6.3%, 14.50 vs 22.00 mm)。中位随访44个月(IQR 22.00-70.00)后,SCT的原发性通畅率最高(1年、3年和5年为100%),而血管内修复(93.4%、88.2%、77.6%)和SCB(94.1%、86.8%、72.3%;p = 0.12)。血管内组原发性通畅、继发性通畅,TLR发生率与开放手术(SCB和SCT)相当。SCB的原发性通畅率低于SCT。结论:血管内修复术具有良好的长期通畅性,但由于技术失败率较高,需要谨慎选择患者。SCT推荐用于血管内衰竭高风险的患者,而SCB仍然适用于多节段、远端闭塞或病变与va长度较短的病变。临床影响据我们所知,这是比较血管内修复、锁骨下颈动脉旁路(SCB)和转位(SCT)治疗SA闭塞的最大研究。我们发现血管内修复提供了与开放手术相当的中期通畅,并且可能是精心挑选的患者的首选-与先前的报道相反,可能是由于优化的抗血小板治疗。技术失败在累及口部或病变长度较长的病例中更为常见。尽管SCB对SCT的开放程度较低,但对于复杂的远端病变或病变到椎动脉(VA)长度较短的病变,SCB仍然是首选。我们的解剖分析可能为个体化治疗选择提供指导。
期刊介绍:
The Journal of Endovascular Therapy (formerly the Journal of Endovascular Surgery) was established in 1994 as a forum for all physicians, scientists, and allied healthcare professionals who are engaged or interested in peripheral endovascular techniques and technology. An official publication of the International Society of Endovascular Specialists (ISEVS), the Journal of Endovascular Therapy publishes peer-reviewed articles of interest to clinicians and researchers in the field of peripheral endovascular interventions.